BioDiem at Portugal flu conference
Tuesday, 16 September, 2008
BioDiem [ASX: BDM] has presented data from the company's influenza vaccine research at the Third European Influenza Conference in Portugal.
The speakers included BioDiem's head of virology and non-executive director, Professor Larisa Rudenko.
Rudenko presented data from BioDiem's studies evaluating the body's immune response to a live attenuated influenza vaccine (LAIV).
The conference heard that the vaccine significantly stimulated the main factors of immunity, including anti-haemagglutination, local antibodies and cell immunity.
The LAIV research was completed at the Institute of Experimental Medicine in St Petersburg, Russia.
Recent years have seen the emergence of highly pathogenic influenza viruses such as avian flu. The LAIV research is an attempt to develop a vaccine that can more effectively fight these influenza strains.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
